Diabetic nephropathy (DN) is one of the most common microvascular complications of diabetes mellitus (DM) and has become the major cause of kidney failure worldwide.[1, 2] However, there are few established options for DN patients, including angiotensin converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and sodium‐dependent glucose transporter 2 (SGLT‐2) inhibitors,[2, 3] with unsatisfactory therapeutic efficacy. The gene discussed is ACE; the disease is diabetes mellitus.